Exact Mass: 371.1205

Exact Mass Matches: 371.1205

Found 67 metabolites which its exact mass value is equals to given mass value 371.1205, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

4-(2-amino-3-hydroxyphenyl)-4-oxobutanoic acid O-glucoside

4-(2-amino-3-{[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}phenyl)-4-oxobutanoic acid

C16H21NO9 (371.1216)


4-(2-amino-3-hydroxyphenyl)-4-oxobutanoic acid O-glucoside, also known as 4-AHPh-oba-glu, is classified as a member of the Phenolic glycosides. Phenolic glycosides are organic compounds containing a phenolic structure attached to a glycosyl moiety. Some examples of phenolic structures include lignans, and flavonoids. Among the sugar units found in natural glycosides are D-glucose, L-Fructose, and L rhamnose. 4-(2-amino-3-hydroxyphenyl)-4-oxobutanoic acid O-glucoside is considered to be slightly soluble (in water) and acidic

   

Baricitinib

2-[1-(Ethanesulphonyl)-3-(4-{1h-pyrrolo[2,3-D]pyrimidin-4-yl}-1H-pyrazol-1-yl)azetidin-3-yl]acetonitrile

C16H17N7O2S (371.1164)


L - Antineoplastic and immunomodulating agents > L04 - Immunosuppressants > L04A - Immunosuppressants > L04AA - Selective immunosuppressants C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor COVID info from Guide to PHARMACOLOGY, clinicaltrial, clinicaltrials, clinical trial, clinical trials, DrugBank C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C172200 - JAK Inhibitor Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

   

(3z)-N,N-Dimethyl-2-Oxo-3-(4,5,6,7-Tetrahydro-1h-Indol-2-Ylmethylidene)-2,3-Dihydro-1h-Indole-5-Sulfonamide

(3Z)-N,N-Dimethyl-2-oxo-3-(4,5,6,7-tetrahydro-1H-indol-2-ylmethylidene)-2,3-dihydro-1H-indole-5-sulphonamide

C19H21N3O3S (371.1304)


   

Cinereapyrrole B

Cinereapyrrole B

C22H17N3O3 (371.127)


   

5-(3-nitrophenyl)-2-phenyl-1,10b-dihydropyrazolo[1,5-c][1,3]benzoxazine

5-(3-nitrophenyl)-2-phenyl-1,10b-dihydropyrazolo[1,5-c][1,3]benzoxazine

C22H17N3O3 (371.127)


   
   

Maybridge4_001514

Maybridge4_001514

C19H21N3O3S (371.1304)


   

SCHEMBL12714883

SCHEMBL12714883

C17H17N5O5 (371.123)


   

Trigonostemine B

Trigonostemine B

C22H17N3O3 (371.127)


   
   
   
   
   

N,N-dimethyl-2-oxo-3-(4,5,6,7-tetrahydro-1H-indol-2-ylmethylidene)-1H-indole-5-sulfonamide

N,N-dimethyl-2-oxo-3-(4,5,6,7-tetrahydro-1H-indol-2-ylmethylidene)-1H-indole-5-sulfonamide

C19H21N3O3S (371.1304)


   
   
   
   
   
   
   

SU 6656

2,3-dihydro-N,N-dimethyl-2-oxo-3-[(4,5,6,7-tetrahydro-1H-indol-2-yl)methylene]-1H-indole-5-sulfonamide

C19H21N3O3S (371.1304)


SU6656 is a Src family kinases inhibitor with IC50s of 280, 20, 130, 170 nM for Src, Yes, Lyn, and Fyn, respectively. SU6656 inhibits FAK phosphorylation at Y576/577, Y925, Y861 sites. SU6656 also inhibits p-AKT.

   

(4-(3-CHLOROPHENYLAMINO)-1-METHYL-1H-IMIDAZO[4,5-C]PYRIDIN-7-YL)(MORPHOLINO)METHANONE

(4-(3-CHLOROPHENYLAMINO)-1-METHYL-1H-IMIDAZO[4,5-C]PYRIDIN-7-YL)(MORPHOLINO)METHANONE

C18H18ClN5O2 (371.1149)


   

3-[[2-[4-(2-phenylethynyl)phenoxy]acetyl]amino]benzoic acid

3-[[2-[4-(2-phenylethynyl)phenoxy]acetyl]amino]benzoic acid

C23H17NO4 (371.1158)


   

ONO-RS-082

ONO-RS-082

C21H22ClNO3 (371.1288)


ONO-RS-082 is an inhibitor of phospholipase A (PLA)[1]. ONO-RS-082 inhibits PLA2 with the IC50 of 1.0 μM, but does not inhibit PLC even at 100 μM[2].

   
   
   

N-((4-NITROPHENYL)SULFONYL)-1-(TERT-BUTYLOXYCARBONYL)PIPERAZINE

N-((4-NITROPHENYL)SULFONYL)-1-(TERT-BUTYLOXYCARBONYL)PIPERAZINE

C15H21N3O6S (371.1151)


   

n6-benzoyl-8-hydroxy-2-deoxyadenosine

n6-benzoyl-8-hydroxy-2-deoxyadenosine

C17H17N5O5 (371.123)


   

N6-Benzoyladenosine

N6-Benzoyladenosine

C17H17N5O5 (371.123)


   

5-O-BENZOYL-3-AZIDO-3-DEOXYTHYMIDINE

5-O-BENZOYL-3-AZIDO-3-DEOXYTHYMIDINE

C17H17N5O5 (371.123)


   

Methyl 4-{5-[bis(2-chloroethyl)amino]-1-methyl-1H-benzimidazol-2- yl}butanoate

Methyl 4-{5-[bis(2-chloroethyl)amino]-1-methyl-1H-benzimidazol-2- yl}butanoate

C17H23Cl2N3O2 (371.1167)


   

Fmoc-cys(et)-oh

Fmoc-cys(et)-oh

C20H21NO4S (371.1191)


   
   

2-[(2-Acetamido-6-oxo-1,6-dihydro-9H-purin-9-yl)methoxy]ethyl benzoate

2-[(2-Acetamido-6-oxo-1,6-dihydro-9H-purin-9-yl)methoxy]ethyl benzoate

C17H17N5O5 (371.123)


   
   

1,5-Naphthyridine-3-carboxamide, 7-((4-fluorophenyl)methyl)-1,2-dihydro-4-hydroxy-N-(2-hydroxyethyl)-1-methyl-2-oxo-

1,5-Naphthyridine-3-carboxamide, 7-((4-fluorophenyl)methyl)-1,2-dihydro-4-hydroxy-N-(2-hydroxyethyl)-1-methyl-2-oxo-

C19H18FN3O4 (371.1281)


   

SU6656

(3z)-N,N-Dimethyl-2-Oxo-3-(4,5,6,7-Tetrahydro-1h-Indol-2-Ylmethylidene)-2,3-Dihydro-1h-Indole-5-Sulfonamide

C19H21N3O3S (371.1304)


SU6656 is a Src family kinases inhibitor with IC50s of 280, 20, 130, 170 nM for Src, Yes, Lyn, and Fyn, respectively. SU6656 inhibits FAK phosphorylation at Y576/577, Y925, Y861 sites. SU6656 also inhibits p-AKT.

   

[5-Amino-1-(4-fluorophenyl)-1H-pyrazol-4-YL](3-{[(2R)-2,3-dihydroxypropyl]oxy}phenyl)methanone

[5-Amino-1-(4-fluorophenyl)-1H-pyrazol-4-YL](3-{[(2R)-2,3-dihydroxypropyl]oxy}phenyl)methanone

C19H18FN3O4 (371.1281)


   

N-[4-[(1,2-dimethyl-5-indolyl)methylsulfamoyl]phenyl]acetamide

N-[4-[(1,2-dimethyl-5-indolyl)methylsulfamoyl]phenyl]acetamide

C19H21N3O3S (371.1304)


   

(R)-N-(3-Indol-1-YL-2-methyl-propyl)-4-sulfamoyl-benzamide

(R)-N-(3-Indol-1-YL-2-methyl-propyl)-4-sulfamoyl-benzamide

C19H21N3O3S (371.1304)


   

(S)-N-(3-Indol-1-YL-2-methyl-propyl)-4-sulfamoyl-benzamide

(S)-N-(3-Indol-1-YL-2-methyl-propyl)-4-sulfamoyl-benzamide

C19H21N3O3S (371.1304)


   

N-[2-(1H-Indol-5-YL)-butyl]-4-sulfamoyl-benzamide

N-[2-(1H-Indol-5-YL)-butyl]-4-sulfamoyl-benzamide

C19H21N3O3S (371.1304)


   

Baricitinib

Baricitinib

C16H17N7O2S (371.1164)


L - Antineoplastic and immunomodulating agents > L04 - Immunosuppressants > L04A - Immunosuppressants > L04AA - Selective immunosuppressants C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor COVID info from Guide to PHARMACOLOGY, clinicaltrial, clinicaltrials, clinical trial, clinical trials, DrugBank C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C172200 - JAK Inhibitor Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

   

(-)-Dehydrodiconiferyl acid

(-)-Dehydrodiconiferyl acid

C20H19O7- (371.1131)


   

(+)-Dehydrodiconiferyl acid

(+)-Dehydrodiconiferyl acid

C20H19O7- (371.1131)


   

Dehydrodiconiferyl acid

Dehydrodiconiferyl acid

C20H19O7- (371.1131)


   

(S)-averantin(1-)

(S)-averantin(1-)

C20H19O7- (371.1131)


A phenolate anion obtained by deprotonation of the 2-hydroxy group of (S)-averantin. It is the major microspecies at pH 7.3 (according to Marvin v 6.2.0.).

   

4-hydroxy-1-(3-methylbutyl)-N-(5-methyl-1,3-thiazol-2-yl)-2-oxo-1,2-dihydroquinoline-3-carboxamide

4-hydroxy-1-(3-methylbutyl)-N-(5-methyl-1,3-thiazol-2-yl)-2-oxo-1,2-dihydroquinoline-3-carboxamide

C19H21N3O3S (371.1304)


   

(5Z)-3-hexyl-5-[(5-phenyl-1H-pyrazol-4-yl)methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one

(5Z)-3-hexyl-5-[(5-phenyl-1H-pyrazol-4-yl)methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one

C19H21N3OS2 (371.1126)


   

5-(2,3-Dihydroindol-1-ylsulfonyl)-1,3-diethyl-2-benzimidazolone

5-(2,3-Dihydroindol-1-ylsulfonyl)-1,3-diethyl-2-benzimidazolone

C19H21N3O3S (371.1304)


   

[4-[[4-(Methylthio)phenyl]methyl]-1-piperazinyl]-(4-nitrophenyl)methanone

[4-[[4-(Methylthio)phenyl]methyl]-1-piperazinyl]-(4-nitrophenyl)methanone

C19H21N3O3S (371.1304)


   

3-Methyl-1-phenyl-5-thieno[2,3-c]pyrazolecarboxylic acid [2-(butylamino)-2-oxoethyl] ester

3-Methyl-1-phenyl-5-thieno[2,3-c]pyrazolecarboxylic acid [2-(butylamino)-2-oxoethyl] ester

C19H21N3O3S (371.1304)


   

Herqueinone(1-)

Herqueinone(1-)

C20H19O7- (371.1131)


   

5-(dimethylamino)-N-[4-(hydroxyamino)benzyl]naphthalene-1-sulfonamide

5-(dimethylamino)-N-[4-(hydroxyamino)benzyl]naphthalene-1-sulfonamide

C19H21N3O3S (371.1304)


   
   
   
   
   
   
   

ent-glycosmisate

ent-glycosmisate

C20H19O7 (371.1131)


A monocarboxylic acid anion that is the conjugate base of ent-glycosmisic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

4-(2-amino-3-hydroxyphenyl)-4-oxobutanoic acid O-glucoside

4-(2-amino-3-hydroxyphenyl)-4-oxobutanoic acid O-glucoside

C16H21NO9 (371.1216)


   

N,N-dimethyl-2-oxo-3-(4,5,6,7-tetrahydro-1H-indol-2-ylmethylene)indoline-5-sulfonamide

N,N-dimethyl-2-oxo-3-(4,5,6,7-tetrahydro-1H-indol-2-ylmethylene)indoline-5-sulfonamide

C19H21N3O3S (371.1304)


   

glycosmisate

glycosmisate

C20H19O7 (371.1131)


A monocarboxylic acid anion that is the conjugate base of glycosmisic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

FITM

FITM

C18H18FN5OS (371.1216)


FITM is a negative allosteric modulator of mGlu1 receptor with a Ki of 2.5 nM.

   

6-methoxy-3-{7-methoxy-9h-pyrido[3,4-b]indole-1-carbonyl}-1h-indole

6-methoxy-3-{7-methoxy-9h-pyrido[3,4-b]indole-1-carbonyl}-1h-indole

C22H17N3O3 (371.127)


   

methyl 3-(5-hydroxy-1h-indol-3-yl)-4-(1h-indol-3-yl)-1h-pyrrole-2-carboxylate

methyl 3-(5-hydroxy-1h-indol-3-yl)-4-(1h-indol-3-yl)-1h-pyrrole-2-carboxylate

C22H17N3O3 (371.127)